The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China

Table 4 Drugs of complete substitution

No.	Round	Generic Name	Brand	DDDc			DDDs
No.	Round	Generic Name	Brand	Before	After	Rate of Change	Before	After	Rate of Change
1	First	Tenofovir disoproxil fumarate tablets	Bid-winning		0.47	-97.15%***		45.00	3.25%***
1	First	Tenofovir disoproxil fumarate tablets	Bid-non-winning	16.33		-97.15%***	43.58		3.25%***
2	First	Montelukast sodium tablets	Bid-winning		3.79	-32.27%***		11.19	13.22%
2	First	Montelukast sodium tablets	Bid-non-winning	5.60		-32.27%***	9.88		13.22%
3	Third	Montelukast sodium oral granules	Bid-winning		1.60	-76.45%***		13.17	-2.41%
3	Third	Montelukast sodium oral granules	Bid-non-winning	6.78		-76.45%***	13.50		-2.41%
4	Third	Ticagrelor tablets	Bid-winning	5.71	1.02	-82.10%***	28.00	41.08	34.14%**
4	Third	Ticagrelor tablets	Bid-non-winning	8.45		-82.10%***	70.00		34.14%**
5	Fifth	Docetaxel injection	Bid-winning	92.67	6.45	-91.96%***	18.74	17.51	-16.04%***
5	Fifth	Docetaxel injection	Bid-non-winning	79.22		-91.96%***	21.03		-16.04%***
6	Fifth	Potassium chloride sustained-release tablets	Bid-winning	2.35	2.03	-4.18%***	7.17	7.91	10.91%***
6	Fifth	Potassium chloride sustained-release tablets	Bid-non-winning	1.36		-4.18%***	7.03		10.91%***

ISSN: 1472-6963